Leading the fight in pulmonary fibrosis

Pacific Therapeutics is a development stage Specialty Pharmaceutical Company focused on the identification and development of drug candidates to treat diseases of excessive scarring (fibrosis).

The lead product candidate PTL-202 is a combination of drugs that have been approved by the FDA for indications other than fibrosis. PTL-202 is being developed to treat the progressive lung scarring disease, Idiopathic pulmonary fibrosis a $2 billion market opportunity.

Pacific is executing a strategy that reduces the risk, time and cost of developing therapies for fibrosis by combining compounds with known safety and toxicity profiles while avoiding the risks associated with basic research.

Stock Offering Summary data sheet - View here

Meet us at the next upcoming events

2010 BioFinance, April 6-8, 2010 - Toronto, Canada